{
  "model": "gemini/gemini-2.0-flash-exp",
  "prompt_version": "v3",
  "prompt_name": "Dual format (rsID + genotype)",
  "timestamp": "2026-01-19T21:17:43.931556",
  "use_supplements": true,
  "use_variant_context": true,
  "per_article_results": [
    {
      "pmcid": "PMC5508045",
      "has_supplement": true,
      "variants": [
        {
          "variant": "rs9923231",
          "variant_context": "Also known as: VKORC1 rs9923231 reference (C), VKORC1 -1252G>A, VKORC1 1639G>A, VKORC1 -1639G>A",
          "generated": "Patients with genotypes AA and GA of VKORC1 -1639G > A (rs9923231) required significantly lower averages of stable weekly doses of warfarin as compared with those with wild-type GG genotype.\n",
          "ground_truth": [
            "Genotypes CT + TT are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism or Venous Thrombosis as compared to genotype CC."
          ],
          "best_similarity": 0.14583333333333334,
          "best_match_idx": 0,
          "best_match": "Genotypes CT + TT are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism or Venous Thrombosis as compared to genotype CC.",
          "all_similarities": [
            0.14583333333333334
          ]
        },
        {
          "variant": "rs1057910",
          "variant_context": "Also known as: CYP2C9 1075A>C, CYP2C9*1",
          "generated": "Genotypes *1/*3 + *3/*3 of CYP2C9 (rs1057910) are associated with decreased dose of warfarin as compared to genotype *1/*1.\n",
          "ground_truth": [
            "Genotypes AC + CC are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype AA."
          ],
          "best_similarity": 0.38235294117647056,
          "best_match_idx": 0,
          "best_match": "Genotypes AC + CC are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype AA.",
          "all_similarities": [
            0.38235294117647056
          ]
        },
        {
          "variant": "rs2108622",
          "variant_context": "",
          "generated": "Genotype TT of rs2108622 is associated with increased dose of warfarin as compared to genotype CC.\n",
          "ground_truth": [
            "Genotype TT is associated with increased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC."
          ],
          "best_similarity": 0.48148148148148145,
          "best_match_idx": 0,
          "best_match": "Genotype TT is associated with increased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC.",
          "all_similarities": [
            0.48148148148148145
          ]
        },
        {
          "variant": "rs887829",
          "variant_context": "Also known as: UGT1A1*80, UGT1A1 -364C>T",
          "generated": "Alleles of UGT1A1 rs887829 are not associated with stable weekly dose of warfarin.\n",
          "ground_truth": [
            "Allele C is not associated with dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to allele T."
          ],
          "best_similarity": 0.1875,
          "best_match_idx": 0,
          "best_match": "Allele C is not associated with dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to allele T.",
          "all_similarities": [
            0.1875
          ]
        }
      ],
      "avg_similarity": 0.29929193899782136
    },
    {
      "pmcid": "PMC554812",
      "has_supplement": false,
      "variants": [
        {
          "variant": "HLA-B*58:01",
          "variant_context": "",
          "generated": "HLA-B*58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.\n",
          "ground_truth": [
            "HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol."
          ],
          "best_similarity": 0.8125,
          "best_match_idx": 0,
          "best_match": "HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.",
          "all_similarities": [
            0.8125
          ]
        },
        {
          "variant": "HLA-DRB1*03:01",
          "variant_context": "",
          "generated": "DRB1*03:01 of HLA-DRB1*03:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.\n",
          "ground_truth": [
            "HLA-DRB1 *03:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol."
          ],
          "best_similarity": 0.7647058823529411,
          "best_match_idx": 0,
          "best_match": "HLA-DRB1 *03:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.",
          "all_similarities": [
            0.7647058823529411
          ]
        },
        {
          "variant": "HLA-C*03:02",
          "variant_context": "",
          "generated": "Cw*03:02 of HLA-C*03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.\n",
          "ground_truth": [
            "HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol."
          ],
          "best_similarity": 0.7647058823529411,
          "best_match_idx": 0,
          "best_match": "HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.",
          "all_similarities": [
            0.7647058823529411
          ]
        },
        {
          "variant": "HLA-A*33:03",
          "variant_context": "",
          "generated": "HLA-A*33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.\n",
          "ground_truth": [
            "HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol."
          ],
          "best_similarity": 0.8125,
          "best_match_idx": 0,
          "best_match": "HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.",
          "all_similarities": [
            0.8125
          ]
        },
        {
          "variant": "rs1594",
          "variant_context": "",
          "generated": "Two SNPs rs2268791 and rs1594 in the CASP8 and FADD-like apoptosis regulator (CFLAR) gene are potentially associated with allopurinol-induced SCAR.\n",
          "ground_truth": [
            "Allele A is associated with severe cutaneous adverse reactions when treated with allopurinol as compared to allele G."
          ],
          "best_similarity": 0.06060606060606061,
          "best_match_idx": 0,
          "best_match": "Allele A is associated with severe cutaneous adverse reactions when treated with allopurinol as compared to allele G.",
          "all_similarities": [
            0.06060606060606061
          ]
        }
      ],
      "avg_similarity": 0.6430035650623885
    }
  ],
  "avg_similarity": 0.4902428423670254,
  "total_variants": 9,
  "articles_with_supplements": 1
}